Home Biochemical properties of endogenous presenilin 1 and presenilin 2 in cultured human B-lymphocytes
Article
Licensed
Unlicensed Requires Authentication

Biochemical properties of endogenous presenilin 1 and presenilin 2 in cultured human B-lymphocytes

  • Lukasz Bojarski , Andrzej Lewandowicz , Magdalena Blazejczyk , Adam Sobczak , Jacek Kuznicki and Urszula Wojda
Published/Copyright: October 1, 2007
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 45 Issue 10

Abstract

Background: Presenilin 1 (PS1) and presenilin 2 (PS2) are membranous proteins involved in the pathology of Alzheimer's disease. The development of specific therapies targeted at PS1 or PS2 requires the determination of biochemical properties of presenilins. Hence, in this study we analyzed the hydrophobic and ionic properties of endogenous presenilins.

Methods: Lysates of immortalized human B-lymphocytes were used as a source of endogenous presenilins. The presence of 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate (CHAPSO) detergent in lysates favored preservation of PS1 and PS2 native protein complexes. We compared Kyte-Doolittle hydropathicity profiles and hydrophobic interactions of PS1 and PS2 with phenyl-agarose. We also compared the ionic properties of presenilins using anion-exchange chromatography.

Results: The hydropathicity profiles of PS1 and PS2 revealed similarly located hydrophobic regions and more hydrophobic region in the C-terminal fragment of PS2. However, both PS1 and PS2 under physiological conditions showed no interactions with phenyl-agarose. Despite similar predicted isoelectric points, PS1 and PS2 exhibited different ionic behavior during anion-exchange chromatography.

Conclusions: The different than expected hydrophobic and ionic behavior of PS1 and PS2 may be caused by interactions with other proteins present in complexes formed by endogenous presenilins. The observed difference in ionic properties of PS1 and PS2 can be further explained assuming that PS1 and PS2 form complexes with different sets of proteins. The composition of such variegated PS1 and PS2 complexes can be explored using a proteomic approach. The difference in PS1 and PS2 ionic behavior can be used for purification of endogenous PS1 from PS2, which has not yet been achieved by any other means.

Clin Chem Lab Med 2007;45:1273–6.


Corresponding author: Urszula Wojda, Laboratory of Neurodegeneration, International Institute of Molecular and Cell Biology, Trojdena 4, 02-109 Warsaw, Poland[ep Phone: +48-22-5970-760, Fax: +48-22-5970-715,

Received: 2006-11-16
Accepted: 2007-4-19
Published Online: 2007-10-01
Published in Print: 2007-10-01

©2007 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Atrial natriuretic peptide and related peptides
  2. The −374A allele of the receptor for advanced glycation end products (RAGE) gene promoter is a protective factor against cardiovascular lesions in type 2 diabetes mellitus patients
  3. Biochemical properties of endogenous presenilin 1 and presenilin 2 in cultured human B-lymphocytes
  4. CD36 polymorphism and its relationship with body mass index and coronary artery disease in a Korean population
  5. Preservation of RNA for functional analysis of separated alleles in yeast: comparison of snap-frozen and RNALater® solid tissue storage methods
  6. Mother-child double incompatibility at vWA and D5S818 loci in paternity testing
  7. Matrix metalloprotease-2 and -9 concentration and activity in serum and culture medium samples: a methodological reappraisal
  8. Are changes in blood-ethanol concentration during storage analytically significant? Importance of method imprecision
  9. Measurement of arginine derivatives in pediatric patients with chronic kidney disease using high-performance liquid chromatography-tandem mass spectrometry
  10. The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia
  11. Calculated low-density lipoprotein cholesterol remains a viable and important test for screening and targeting therapy
  12. Angiotensin-converting enzyme (ACE) I/D corrected serum ACE activity and severity assessment of community-acquired pneumonia
  13. Differentiating transudative from exudative pleural effusion: should we measure effusion cholesterol dehydrogenase?
  14. Association of classical and related inflammatory markers with high-sensitivity C-reactive protein in healthy individuals: results from the Stanislas cohort
  15. Cytokines and growth factors in mostly atherosclerotic patients on hemodialysis determined by biochip array technology
  16. Use of a solid-phase extraction with radioimmunoassay to identify the proportional bias of clinical B-type natriuretic peptide immunoassay: the impact of plasma matrix and antibody multispecificity
  17. High plasma levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and interleukin-8 (IL-8) characterize patients prone to ventricular fibrillation complicating myocardial infarction
  18. Methylprednisolone, cortisol and the cell-mediated immune response in children after ventricular septal defect repair
  19. Standardization of γ-glutamyltransferase assays by intermethod calibration. Effect on determining common reference limits
  20. The effect of endurance exercise-induced lactacidosis on biochemical markers of bone turnover
  21. Serum biobank certification and the establishment of quality controls for biological fluids: examples of serum biomarker stability after temperature variation
  22. Diagnostic usefulness of a third-generation anti-cyclic citrulline antibody test in patients with recent-onset polyarthritis
  23. Clinical significance of the laboratory determination of low serum copper in adults
  24. National survey on critical values reporting in a cohort of Italian laboratories
  25. Influence of haemodialysis on the NT-proBNP plasma concentration
  26. C–588T polymorphism of the human glutamate-cysteine ligase modifier subunit gene is not associated with the risk and extent of ischemic heart disease in a German cohort
  27. Has homocysteine shrunk?
Downloaded on 10.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2007.506/html
Scroll to top button